BioMarin Pharmaceutical Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
BioMarin Pharmaceutical wird ein jährliches Gewinn- und Umsatzwachstum von 32.4% bzw. 10.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 33.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12% betragen.
Wichtige Informationen
32.4%
Wachstumsrate der Gewinne
33.11%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 29.0% |
| Wachstumsrate der Einnahmen | 10.3% |
| Zukünftige Eigenkapitalrendite | 12.00% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 10 Sep 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrative-Update • Sep 05
BMRN: Royalty Settlement On Skeletal Therapies Will Recast Earnings Power
Analysts have modestly lifted the fair value estimate for BioMarin Pharmaceutical to $91.42 per share from $87.85, citing updated assumptions that factor in the Yuviwel royalty settlement, a higher future P/E multiple, and adjusted revenue growth and margin expectations. Analyst Commentary Recent Street research on BioMarin Pharmaceutical has centered on the Yuviwel royalty settlement, Voxzogo intellectual property, and the integration of Amicus and Alesta.
Narrative-Update • Aug 22
BMRN: Alesta Integration And ALE1 Uncertainty Will Weigh On Future Sentiment
Analysts have lifted their fair value estimate for BioMarin Pharmaceutical stock to $59, reflecting updated assumptions around Voxzogo durability, the contribution from Amicus assets, and potential cost synergies following the Alesta acquisition. Analyst Commentary Recent Street research on BioMarin Pharmaceutical reflects a mix of optimism around the Voxzogo franchise, the Amicus portfolio and cost synergies from the Alesta deal, alongside pockets of caution around execution risk and valuation.
Narrative-Update • Aug 07
BMRN: Rare Disease Portfolio And Pipeline Progress Will Drive Repricing
Analysts have modestly raised the fair value estimate for BioMarin Pharmaceutical to $124 from $120. This reflects updated price targets that point to steady confidence in the company's product portfolio and near term growth drivers.Seeking Alpha • Jul 22
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset
Summary BioMarin is evolving into a scalable rare-disease commercialization platform, leveraging its infrastructure for new product launches and lifecycle management. The $4.8B Amicus acquisition adds GALAFOLD and POMBILITI/OPFOLDA, driving revenue growth and operating leverage, but increases near-term financial risk. VOXZOGO's expansion into hypochondroplasia and ongoing lifecycle management underpin a robust skeletal franchise, despite intensifying competition and upcoming regulatory milestones. BMRN trades at a material valuation discount to biotech peers despite 20% 2026 revenue growth guidance, with upside dependent on execution, Amicus integration, and franchise defense. Read the full article on Seeking AlphaAnalyseartikel • Jun 16
BioMarin Pharmaceutical (BMRN) Stock Could Be 36.7% Undervalued After ENDO 2026 Data
BioMarin Pharmaceutical (BMRN) drew fresh attention after presenting new VOXZOGO and BMN 333 data at ENDO 2026, reinforcing its focus on rare bone growth disorders and raising new questions for investors. See our latest analysis for BioMarin Pharmaceutical. Against this backdrop, BioMarin Pharmaceutical’s 1 month share price return of 7.41% stands in contrast to a year to date share price decline of 6.39%. Over 3 years, the total shareholder return is down 42.21%, suggesting momentum has been...Narrative-Update • Jun 15
BMRN: Voxzogo Hypochondroplasia Data Will Recast Earnings Power Despite Franchise Uncertainty
BioMarin Pharmaceutical's analyst price target edged lower by about $2 as analysts weighed the strong Phase 3 Voxzogo data against more cautious outlooks for BMN401, following mixed ENPP1 deficiency results and reduced contribution in several revised models. Analyst Commentary Recent research updates present a split picture on BioMarin, with analysts reassessing price targets as they balance strong Voxzogo Phase 3 data against a more cautious stance on BMN401 in ENPP1 deficiency.Narrative-Update • Jun 01
BMRN: Mixed ENPP1 Outcomes Will Pressure Sentiment Despite Hypochondroplasia Progress
Analysts have trimmed the fair value estimate for BioMarin Pharmaceutical from about $55.36 to $50.23 as they adjust models for mixed BMN401 Phase 3 data, a slightly higher discount rate, more moderate revenue growth and profit margin assumptions, and a higher future P/E multiple aligned with recent price target changes across the Street. Analyst Commentary Recent Street research reflects a split view on BioMarin Pharmaceutical, with several firms trimming price targets and revisiting assumptions after mixed clinical updates, particularly around BMN401 in ENPP1 deficiency and Voxzogo studies in other indications.Narrative-Update • May 14
BMRN: Pending Amicus Acquisition Will Recast Earnings Power Despite Treatment Franchise Uncertainty
Analysts have nudged their fair value estimate for BioMarin Pharmaceutical to $89.96, reflecting updated assumptions on discount rate, revenue growth, profit margins, and a higher future P/E following a mix of recent price target increases and reductions across the Street. Analyst Commentary Street research on BioMarin Pharmaceutical has been active, with a mix of higher and lower price targets and one recent coverage reinstatement at Goldman Sachs.Narrative-Update • Apr 29
BMRN: Fair Value View Weighs Voxzogo Headwinds Against Amicus Acquisition Potential
Analysts have trimmed their average price target on BioMarin Pharmaceutical slightly, cutting fair value by about $0.30 to $55.36. They are factoring in a higher discount rate, modestly stronger long term growth and margins, and a slightly lower future P/E multiple following recent reassessments of the Voxzogo franchise and the planned Amicus acquisition.Narrative-Update • Apr 15
BMRN: Fair Value View Balances Voxzogo Risks And Amicus Opportunity
The analyst fair value estimate for BioMarin Pharmaceutical has been trimmed from about $60 to roughly $55.66 as analysts factor in a higher discount rate, a lower future P/E multiple, and mixed expectations around Voxzogo and the Amicus acquisition. Analyst Commentary Recent research on BioMarin reflects a mixed but generally constructive stance, with several firms revising price targets while keeping positive ratings.Narrative-Update • Apr 01
BMRN: Pending Amicus Deal Will Reshape Earnings Power Despite Treatment Franchise Risks
Analyst revisions point to a slightly lower blended fair value for BioMarin Pharmaceutical, trimming the price target by about $0.09 as analysts factor in mixed views on Voxzogo and the pending Amicus deal while keeping underlying growth, margin, and P/E assumptions broadly unchanged. Analyst Commentary Recent Street research reflects a split view on BioMarin, with most analysts still constructive on long term value creation while others focus on Voxzogo related risks and competitive pressures.Narrative-Update • Mar 18
BMRN: Amicus Acquisition Is Expected To Reshape Future Earnings Power
Analysts have nudged their fair value estimate for BioMarin to $88.96 from $88.65, citing updates to revenue growth, profit margin and future P/E assumptions as they reassess Voxzogo risks, competitive pressure and the potential impact of the Amicus acquisition. Analyst Commentary Recent street research paints a mixed picture for BioMarin, with analysts recalibrating expectations around Voxzogo, the Amicus acquisition and the broader rare disease portfolio.Narrative-Update • Mar 03
BMRN: Rare Disease Portfolio Expansion And Amicus Acquisition Will Drive Repricing
Our BioMarin Pharmaceutical update trims the fair value estimate slightly to $120 from $122, as analysts weigh higher long term growth and margin assumptions against a higher discount rate and a lower future P/E multiple. Recent Street price target moves now cluster in the mid to high $90s, with outliers as low as $55 and as high as $105.Narrative-Update • Feb 17
BMRN: Recent Coverage Shifts Will Support Higher Future Earnings Multiple
Analysts have trimmed their fair value estimate for BioMarin Pharmaceutical by roughly $2 to about $88.65. This reflects updated views on discount rates, revenue growth, profit margins, and future P/E assumptions drawn from recent Street research.Narrative-Update • Feb 03
BMRN: Shares Should Recover As Fresh Coverage Supports Higher Future Earnings Multiple
Analysts have lifted their price target for BioMarin Pharmaceutical by about US$1 to roughly US$91, citing updated assumptions around revenue growth, margins and a higher future P/E multiple, supported by recent positive Street research coverage. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent Street coverage as support for using a higher future P/E multiple, which feeds directly into a slightly higher fair value range around US$91.Narrative-Update • Jan 20
BMRN: Reset Long Term Outlook Will Shape Risk Balance Going Forward
Analysts have reduced their price target on BioMarin Pharmaceutical to US$60 from US$67.39 as they factor in updated long term revenue scenarios, a higher discount rate, and slightly stronger margin assumptions following recent quarterly results and guidance changes. Analyst Commentary Recent Street research shows a cluster of price target cuts on BioMarin, generally following an "okay" Q3 print, a Q3 revenue miss in some areas, and updated long term guidance that now reflects a wider range of possible competitive and intellectual property outcomes.Narrative-Update • Jan 06
BMRN: Shares Should Recover As 2027 Revenue Reset Clarifies Competition Risk
Analysts now see fair value for BioMarin Pharmaceutical at $89.74 per share, a small move up that reflects lower long term revenue growth assumptions, a slightly higher profit margin outlook, and modestly higher future P/E expectations following recent price target cuts tied to Voxzogo trends, revised 2027 revenue guidance, and potential competition. Analyst Commentary Recent Street research shows a wide range of views on BioMarin, with a clear focus on Voxzogo trends, updated 2027 revenue scenarios, and the impact of potential competition on execution and valuation.Narrative-Update • Dec 16
BMRN: Shares Will Strengthen As 2025 Guidance Reset Supports Future Upside
Analysts have trimmed their average price target on BioMarin Pharmaceutical by roughly $1 to reflect a modest reset in long term revenue and margin expectations after Q3’s revenue miss, Voxzogo softness and greater acknowledgment of emerging competitive risks, even though they continue to view the shares as undervalued. Analyst Commentary Analyst reactions to BioMarin’s Q3 update reflect a more nuanced view of the company’s medium term growth profile, with reduced price targets but largely constructive ratings as investors recalibrate for competitive dynamics and updated long range guidance.Narrative-Update • Dec 02
BMRN: Shares Will Strengthen As 2025 Guidance and Pipeline Progress Drive Upside
BioMarin Pharmaceutical's analyst price target has been reduced from $90.50 to $89.36. Analysts cite slightly lower growth and profit margin expectations, new competitive pressures, and revised long-term guidance as key drivers for the change.Narrative-Update • Nov 18
BMRN: Shares Will Recover As Revenue Guidance Aligns With Market Expectations
Analysts have modestly reduced their price target for BioMarin Pharmaceutical, trimming it by $0.10 to $90.50. Recent updates reflect a more cautious outlook on revenue growth and profit margins in light of evolving competitive and regulatory expectations.Narrative-Update • Nov 03
BMRN: Revenue Guidance Revision Will Reveal New Competitive Dynamics Ahead
Analysts have lowered their average price target for BioMarin Pharmaceutical from about $94.80 to $90.60. This reflects a cautious view following revenue misses, reduced long-term guidance due to anticipated competition, and updated profit margin forecasts.Analyseartikel • Oct 30
Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts
Last week, you might have seen that BioMarin Pharmaceutical Inc. ( NASDAQ:BMRN ) released its quarterly result to the...Narrative-Update • Oct 20
Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
BioMarin Pharmaceutical's analyst price target was revised slightly lower, decreasing from $95.16 to $94.80 per share as analysts weighed ongoing competitive risks to Voxzogo and modest changes to key financial assumptions. Analyst Commentary Recent analyst coverage of BioMarin Pharmaceutical reflects a mix of optimism and caution surrounding the company's future prospects, especially regarding its growth story, competitive landscape, and valuation relative to peers.Narrative-Update • Oct 05
Pipeline Progress And Regulatory Support Will Unlock Rare Disease Opportunities
Analysts have slightly lowered their price target for BioMarin Pharmaceutical to $95.16. This adjustment reflects carefully balanced views on future revenue growth, competitive risks affecting key drugs, and the company's ongoing potential for pipeline advancement.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 4,833 | 1,175 | 1,334 | 1,232 | 19 |
| 12/31/2027 | 4,466 | 917 | 1,082 | 1,066 | 24 |
| 12/31/2026 | 3,909 | 570 | 463 | 713 | 24 |
| 6/30/2026 | 3,407 | 73 | 725 | 857 | N/A |
| 3/31/2026 | 3,242 | 269 | 759 | 874 | N/A |
| 12/31/2025 | 3,221 | 349 | 717 | 828 | N/A |
| 9/30/2025 | 3,094 | 520 | 826 | 914 | N/A |
| 6/30/2025 | 3,064 | 657 | 691 | 767 | N/A |
| 3/31/2025 | 2,950 | 524 | 620 | 700 | N/A |
| 12/31/2024 | 2,854 | 427 | 485 | 573 | N/A |
| 9/30/2024 | 2,753 | 322 | 311 | 415 | N/A |
| 6/30/2024 | 2,588 | 257 | 223 | 329 | N/A |
| 3/31/2024 | 2,472 | 205 | 173 | 280 | N/A |
| 12/31/2023 | 2,419 | 168 | 52 | 159 | N/A |
| 9/30/2023 | 2,311 | 147 | 25 | 139 | N/A |
| 6/30/2023 | 2,235 | 100 | 34 | 161 | N/A |
| 3/31/2023 | 2,173 | 72 | 15 | 147 | N/A |
| 12/31/2022 | 2,096 | 142 | 148 | 176 | N/A |
| 9/30/2022 | 2,008 | 84 | 151 | 180 | N/A |
| 6/30/2022 | 1,912 | 54 | 106 | 119 | N/A |
| 3/31/2022 | 1,880 | 39 | 134 | 146 | N/A |
| 12/31/2021 | 1,846 | -64 | 185 | 305 | N/A |
| 9/30/2021 | 1,849 | 16 | 165 | 280 | N/A |
| 6/30/2021 | 1,917 | 837 | 155 | 269 | N/A |
| 3/31/2021 | 1,844 | 795 | 92 | 214 | N/A |
| 12/31/2020 | 1,860 | 854 | 15 | 85 | N/A |
| 9/30/2020 | 1,863 | 852 | 75 | 156 | N/A |
| 6/30/2020 | 1,847 | 122 | 58 | 140 | N/A |
| 3/31/2020 | 1,805 | 114 | N/A | 88 | N/A |
| 12/31/2019 | 1,704 | -24 | N/A | 48 | N/A |
| 9/30/2019 | 1,603 | -43 | N/A | 40 | N/A |
| 6/30/2019 | 1,533 | -110 | N/A | 17 | N/A |
| 3/31/2019 | 1,519 | -90 | N/A | 8 | N/A |
| 12/31/2018 | 1,491 | -77 | N/A | 20 | N/A |
| 9/30/2018 | 1,496 | -125 | N/A | -15 | N/A |
| 6/30/2018 | 1,439 | -125 | N/A | -23 | N/A |
| 3/31/2018 | 1,383 | -145 | N/A | 29 | N/A |
| 12/31/2017 | 1,314 | -117 | N/A | -9 | N/A |
| 9/30/2017 | 1,255 | -156 | N/A | -24 | N/A |
| 6/30/2017 | 1,201 | -181 | N/A | -72 | N/A |
| 3/31/2017 | 1,184 | -563 | N/A | -137 | N/A |
| 12/31/2016 | 1,117 | -630 | N/A | -228 | N/A |
| 9/30/2016 | 1,045 | -471 | N/A | -293 | N/A |
| 6/30/2016 | 974 | -524 | N/A | -286 | N/A |
| 3/31/2016 | 924 | -187 | N/A | -253 | N/A |
| 12/31/2015 | 890 | -172 | N/A | -219 | N/A |
| 9/30/2015 | 892 | -310 | N/A | -179 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BMRNDas prognostizierte Gewinnwachstum (32.4% pro Jahr) liegt über der Sparquote (3.7%).
Ertrag vs. Markt: BMRNDie Erträge des Unternehmens (32.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (17.2% pro Jahr).
Hohe Wachstumserträge: BMRNEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: BMRNDie Einnahmen des Unternehmens (10.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (13.4% pro Jahr).
Hohe Wachstumseinnahmen: BMRNDie Einnahmen des Unternehmens (10.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: BMRNDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (12%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/14 23:36 |
| Aktienkurs zum Tagesende | 2026/09/14 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
BioMarin Pharmaceutical Inc. wird von 45 Analysten beobachtet. 24 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jack Allen | Baird |
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |